Incyte Corporation (NASDAQ:INCY) EVP Barry P. Flannelly sold 714 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $124.25, for a total transaction of $88,714.50. Following the transaction, the executive vice president now owns 15,496 shares of the company’s stock, valued at approximately $1,925,378. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Incyte Corporation (INCY) traded down 0.51% during mid-day trading on Friday, reaching $119.15. 2,995,901 shares of the company traded hands. Incyte Corporation has a 12-month low of $81.49 and a 12-month high of $153.15. The stock’s market capitalization is $24.51 billion. The company’s 50-day moving average is $127.40 and its 200-day moving average is $130.21.
Incyte Corporation (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $326.40 million during the quarter, compared to the consensus estimate of $318.45 million. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. Incyte Corporation’s revenue for the quarter was up 32.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.18 EPS. Equities analysts predict that Incyte Corporation will post ($0.84) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://transcriptdaily.com/2017/09/16/incyte-corporation-incy-evp-barry-p-flannelly-sells-714-shares.html.
INCY has been the subject of several analyst reports. Morgan Stanley restated an “overweight” rating and set a $142.00 price target on shares of Incyte Corporation in a report on Friday, May 19th. J P Morgan Chase & Co restated a “buy” rating and set a $149.00 price target on shares of Incyte Corporation in a report on Thursday, August 31st. Zacks Investment Research upgraded shares of Incyte Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, May 23rd. BMO Capital Markets reaffirmed an “outperform” rating and set a $172.00 price objective on shares of Incyte Corporation in a research report on Monday, August 28th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “hold” rating and set a $135.00 price objective on shares of Incyte Corporation in a research report on Thursday, August 31st. Eight equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $142.16.
A number of institutional investors and hedge funds have recently bought and sold shares of INCY. US Bancorp DE raised its holdings in Incyte Corporation by 67.1% in the first quarter. US Bancorp DE now owns 2,931 shares of the biopharmaceutical company’s stock worth $392,000 after purchasing an additional 1,177 shares in the last quarter. UBS Asset Management Americas Inc. raised its holdings in Incyte Corporation by 23.9% in the first quarter. UBS Asset Management Americas Inc. now owns 1,477,461 shares of the biopharmaceutical company’s stock worth $197,492,000 after purchasing an additional 284,796 shares in the last quarter. Gabelli Funds LLC bought a new position in Incyte Corporation in the first quarter worth $1,109,000. Sei Investments Co. raised its holdings in Incyte Corporation by 49.0% in the first quarter. Sei Investments Co. now owns 27,387 shares of the biopharmaceutical company’s stock worth $3,661,000 after purchasing an additional 9,012 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its holdings in Incyte Corporation by 22.0% in the first quarter. Parametric Portfolio Associates LLC now owns 175,657 shares of the biopharmaceutical company’s stock worth $23,480,000 after purchasing an additional 31,727 shares in the last quarter. Institutional investors and hedge funds own 91.06% of the company’s stock.
Incyte Corporation Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.